SEAL™IT: Saccular Endovascular Aneurysm Lattice System Interventional Pivotal Trial
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 279 participants.
Also called NCT05831202
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 279 participants
- Sponsor
- Galaxy Therapeutics INC
- Registry
-
NCT05831202
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT05831202. Allocation not applicable; no masking; primary purpose treatment. Start 2024-08-06 (actual); primary completion 2026-09-10 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- SEAL™IT: Saccular Endovascular Aneurysm Lattice System Interventional Pivotal Trial
- Acronym
- SEAL™IT
- Condition
- Intracranial Aneurysm
- Intervention (Device)
- The SEAL™ Saccular Endovascular Aneurysm Lattice System
- Lead sponsor
- Galaxy Therapeutics INC
Record details
- Record id
cardio:ct-nct05831202- Content hash
91ed01578b5d387b4b9f0d41589aa6b6be2f681a7192a2b832bcec750ef8e4b5